 | | | | Related Healthscout Videos | |
|
Page: << Prev | 1 | 2 In an article accompanying the study, experts added that "the safety and efficacy of sunitinib in an older population are confirmed and evidence shows that age alone should not be a deterrent from attempting therapy."
But "patients with brain metastases, non-clear-cell histology, and poor performance status benefit less from sunitinib, despite good drug tolerance, suggesting the need for prospective studies in these subpopulations," wrote Dr. Joaquim Bellmunt of Hospital del Mar in Barcelona, Spain, and the Dana-Farber Cancer Institute and Harvard Medical School in Boston, and Dr. Toni K. Choueiri of Dana-Farber and Harvard.
"Thus, claiming sunitinib as a 'standard' in these subgroups remains controversial. An oncologist might not have access to such trials in practice, however, and based on available information the use of sunitinib may be justified in these subpopulations," they concluded.
Text Continues Below
More information
The U.S. National Cancer Institute has more about kidney cancer.
Page: << Prev | 1 | 2
-- Robert Preidt
|
.gif)
